Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$12.38 - $29.19 $184,573 - $435,193
-14,909 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$15.07 - $21.71 $224,678 - $323,674
14,909 New
14,909 $323,000
Q2 2020

Aug 14, 2020

SELL
$12.39 - $17.33 $518,608 - $725,381
-41,857 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$9.12 - $17.78 $91,272 - $177,942
-10,008 Reduced 19.3%
41,857 $553,000
Q4 2019

Feb 13, 2020

BUY
$16.11 - $25.98 $168,623 - $271,932
10,467 Added 25.28%
51,865 $836,000
Q3 2019

Nov 13, 2019

SELL
$18.28 - $26.91 $1.1 Million - $1.61 Million
-59,941 Reduced 59.15%
41,398 $757,000
Q2 2019

Aug 08, 2019

SELL
$17.68 - $21.57 $404,783 - $493,845
-22,895 Reduced 18.43%
101,339 $2.18 Million
Q1 2019

May 13, 2019

BUY
$14.41 - $19.64 $6,239 - $8,504
433 Added 0.35%
124,234 $2.44 Million
Q4 2018

Feb 14, 2019

BUY
$12.45 - $23.47 $206,993 - $390,212
16,626 Added 15.51%
123,801 $1.61 Million
Q3 2018

Nov 13, 2018

BUY
$17.57 - $23.95 $162,294 - $221,226
9,237 Added 9.43%
107,175 $2.57 Million
Q2 2018

Aug 13, 2018

SELL
$11.6 - $19.27 $6,612 - $10,983
-570 Reduced 0.58%
97,938 $1.88 Million
Q1 2018

May 14, 2018

SELL
$11.77 - $16.08 $23,186 - $31,677
-1,970 Reduced 1.96%
98,508 $1.22 Million
Q4 2017

Feb 13, 2018

SELL
$11.86 - $14.08 $15,761 - $18,712
-1,329 Reduced 1.31%
100,478 $1.23 Million
Q3 2017

Nov 13, 2017

SELL
$12.6 - $16.34 $2,746 - $3,562
-218 Reduced 0.21%
101,807 $1.39 Million
Q2 2017

Aug 14, 2017

SELL
N/A
-18,609 Reduced 15.43%
102,025 $1.57 Million
Q1 2017

Apr 17, 2019

SELL
N/A
-139,825 Reduced 53.68%
120,634 $2.22 Million
Q4 2016

Apr 17, 2019

SELL
N/A
-117,284 Reduced 31.05%
260,459 $2.42 Million
Q3 2016

Apr 17, 2019

BUY
N/A
377,743
377,743 $3.15 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $260M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.